Profitelligence Profitelligence · Filing Ledger Open RVMD research →

Form 4 · Statement of Changes in Beneficial Ownership · Filed 2026-09-22

Anderson Elizabeth M Files Revolution Medicines (RVMD) Form 4 - September 22, 2026

Anderson Elizabeth M traded 15.2K RVMD shares worth $2.0M in this Form 4 filing, reported to the SEC on 2026-09-22.

Issuer
Revolution Medicines, Inc. RVMD · NASDAQ
Filed
Period
2026-09-22
Accession
0001758247-26-000004

Transactions (7)

Insider Date Type Shares Price Value Own
Anderson Elizabeth M 2026-09-22 Buy 5.1K $1.12 $5.7K Direct
Anderson Elizabeth M 2026-09-22 Sell 910 $191.85 $174.6K Direct
Anderson Elizabeth M 2026-09-22 Sell 5.0K $192.54 $959.8K Direct
Anderson Elizabeth M 2026-09-22 Sell 2.6K $193.44 $512.2K Direct
Anderson Elizabeth M 2026-09-22 Sell 1.5K $194.59 $291.9K Direct
Anderson Elizabeth M 2026-09-22 Sell 100 $195.15 $19.5K Direct
Net change−5.1K−$2.0M

About Revolution Medicines, Inc.

Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing targeted therapies for RAS-addicted cancers. The company applies proprietary drug discovery capabilities to create small-molecule medicines designed to act on challenging RAS pathway targets, a central driver in many aggressive tumors. Its current pipeline includes RAS(ON) inhibitors and companion inhibitors being studied as monotherapies and in combination regimens to address cancers with specific RAS mutations and related pathway dependencies. Revolution Medicines concentrates on areas of high unmet medical need, including pancreatic, lung, and colorectal cancers, and its work is aimed at improving how these diseases are treated in modern oncology practice. Headquartered in Redwood City, California, and founded in 2014, Revolution Medicines occupies a specialized position in the biotechnology sector through its focus on advanced precision medicine approaches.

Exchange NASDAQ Industry Biotechnology Company website ↗

Track RVMD insider activity

Get alerted when Revolution Medicines, Inc. executives buy or sell their shares.

Set up free alerts